

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): May 27, 2011

**Enzo Biochem, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

New York

(State or Other Jurisdiction of Incorporation)

001-09974

13-2866202

(Commission File Number)

(IRS Employer Identification No.)

527 Madison Avenue  
New York, New York

10022

(Address of Principal Executive Offices)

(Zip Code)

(212) 583-0100

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On May 27, 2011, Dr. Kevin Krenitsky resigned as President of Enzo Clinical Labs, a wholly-owned subsidiary of Enzo Biochem, Inc. (the “Company”). Dr. Krenitsky did not resign because of any disagreement with the Company on any matter relating to the Company’s operations, policies, or practices. Dr. Krenitsky has left Enzo Clinical Labs to pursue another business opportunity. Dr. Krenitsky’s responsibilities at the Enzo Clinical Labs organization will be assumed by Mr. David C. Goldberg, the Company’s Vice President, Corporate Development.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 3, 2011

ENZO BIOCHEM, INC.

By: /s/ Barry Weiner

---

Barry Weiner  
President, Chief Financial Officer,  
Principal Accounting Officer and Director

---